Spots Global Cancer Trial Database for endometrioid adenocarcinoma

Every month we try and update this database with for endometrioid adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.	NCT04458597	Endometrioid Ad... Serous Carcinom... Clear Cell Carc... Carcinosarcoma Dedifferentiate...	Image-guided ad...	18 Years -	Lawson Health Research Institute
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.	NCT04458597	Endometrioid Ad... Serous Carcinom... Clear Cell Carc... Carcinosarcoma Dedifferentiate...	Image-guided ad...	18 Years -	Lawson Health Research Institute
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	NCT05112601	Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom...	Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)	NCT03824704	Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad...	Rucaparib Nivolumab	18 Years -	pharmaand GmbH
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer	NCT01440998	Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Endometrioid Ad... Recurrent Uteri... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri...	Carboplatin Dasatinib Laboratory Biom... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers	NCT03748186	Ovarian Cancer Ovarian Carcino... Ovary Cancer Endometrial Can... Endometrioid Ad... Fallopian Tube ... Primary Periton...	STRO-002	18 Years -	Sutro Biopharma, Inc.
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	NCT05112601	Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom...	Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers	NCT03748186	Ovarian Cancer Ovarian Carcino... Ovary Cancer Endometrial Can... Endometrioid Ad... Fallopian Tube ... Primary Periton...	STRO-002	18 Years -	Sutro Biopharma, Inc.
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	NCT02834013	Acinar Cell Car... Adenoid Cystic ... Adrenal Cortica... Adrenal Gland P... Anal Canal Neur... Anal Canal Undi... Angiosarcoma Apocrine Neopla... Appendix Mucino... Bartholin Gland... Basal Cell Carc... Bladder Adenoca... Breast Metaplas... Cervical Adenoc... Cholangiocarcin... Chordoma Colorectal Squa... Desmoid Fibroma... Endometrial Tra... Endometrioid Ad... Esophageal Neur... Esophageal Undi... Extrahepatic Bi... Extramammary Pa... Fallopian Tube ... Fallopian Tube ... Fibromyxoid Tum... Gallbladder Car... Gastric Neuroen... Gastric Squamou... Gastric Undiffe... Gastrointestina... Gestational Tro... Giant Cell Carc... Human Papilloma... Intestinal Neur... Intrahepatic Ch... Lung Neuroendoc... Lung Sarcomatoi... Major Salivary ... Malignant Odont... Malignant Perip... Malignant Solid... Malignant Testi... Metastatic Mali... Metastatic Pitu... Minimally Invas... Mixed Mesoderma... Mucinous Adenoc... Mucinous Cystad... Nasal Cavity Ad... Nasal Cavity Ca... Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Oral Cavity Car... Oropharyngeal U... Ovarian Adenoca... Ovarian Germ Ce... Ovarian Mucinou... Ovarian Squamou... Ovarian Transit... Pancreatic Acin... Pancreatic Neur... Paraganglioma Paranasal Sinus... Paranasal Sinus... Parathyroid Gla... PEComa Penile Squamous... Peritoneal Meso... Placental Chori... Primary Periton... Pseudomyxoma Pe... Rare Disorder Scrotal Squamou... Seminal Vesicle... Seminoma Serous Cystaden... Small Intestina... Small Intestina... Spindle Cell Ne... Teratoma With S... Testicular Non-... Thyroid Gland C... Tracheal Carcin... Transitional Ce... Ureter Adenocar... Ureter Squamous... Urethral Adenoc... Urethral Squamo... Vaginal Adenoca... Vaginal Squamou... Vulvar Carcinom...	Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers	NCT03345784	Cervical Carcin... Endometrioid Ad... Malignant Femal... Recurrent Cervi... Stage I Uterine... Stage I Vaginal... Stage IA Uterin... Stage IB Cervic... Stage IB Uterin... Stage IB2 Cervi... Stage II Cervic... Stage II Uterin... Stage II Vagina... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage III Uteri... Stage III Vagin... Stage IIIA Cerv... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Uter... Stage IIIC Uter... Vaginal Carcino...	Adavosertib Cisplatin External Beam R...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	NCT05001282	Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Endometrial Can... Ovary Cancer Ovary Neoplasm Ovary Disease Ovary Metastasi... Ovarian Disease... Ovarian Cancer ... Ovarian Epithel... Ovarian Adenoca... Ovarian Serous ... Ovarian Neoplas... Ovarian Cancer ... Endometrial Dis... Endometrial Ade... Endometrial Car... Endometrial Cle... Endometrioid Ad... Endometrial Neo... Endometrial Can... Endometrioid Tu... Fallopian Tube ... Peritoneal Canc...	ELU001	18 Years -	Elucida Oncology
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	NCT05112601	Endometrial Ade... Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Muc... Endometrial Und... Endometrioid Ad... Recurrent Endom...	Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)	NCT03824704	Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad...	Rucaparib Nivolumab	18 Years -	pharmaand GmbH
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease	NCT04291612	Endometrial Can... Endometrioid Ad... Endometrial Can...	Physical exam	18 Years -	Memorial Sloan Kettering Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: